Regorafenib-monohydrate-Standard-生命科學試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemERegorafenibmonohydrate(Standard)Cat.No.:HY-10331ARCASNo.:1019206-88-2分?式:C??H??ClF?N?O?分?量:500.83作?靶點:VEGFR;Autophagy;PDGFR;Raf;RET;FGFR;c-Kit;Tie作?通路:ProteinTyrosineKinase/RTK;Autophagy;MAPK/ERKPathway儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Regorafenib(monohydrate)(Standard)Regorafenib(monohydrate)的分析標準品。本產品?于研究及分析應?。Regorafenib(BAY73-4506)monohydrate?種?服有效的多靶點受體酪氨酸激酶(tyrosinekinase)抑制劑，抑制VEGFR1/2/3，PDGFRβ，Kit，RET和Raf-1的IC50分別為13/4.2/46，22，7，1.5和2.5nM。Regorafenibmonohydrate顯?出?常強的抗腫瘤和抗?管?成活性[1]。IC50&TargetIC50:1.5±0.7nM(RET),2.5±0.6nM(Raf-1),4.2±1.6nM(VEGFR2),7±2nM(Kit),13±0.4nM(VEGFR1),19±6nM(B-RAFV600E),22±3nM(PDGFRβ),28±10nM(B-RAF),46±10nM(VEGFR3),202±18nM(FGFR1),311±46nM(TIE2)[1]REFERENCES[1].WilhelmSM,etal.Regorafenib(BAY73-4506):aneworalmultikinaseinhibitorofangiogenic,stromalandoncogenicreceptortyrosinekinaseswithpotentpreclinicalantitumoractivity.IntJCancer,2011,129(1),245-255.[2].HengDY,etal.Targetedtherapyformetastaticrenalcellcarcinoma:currenttreatmentandfuturedirections.TherAdvMedOncol,2010,2(1),39-49.[3].CarrBI,etal.Fluoro-Bay43-9006(Regorafenib)effectsonhepatomacells:growthinhibition,quiescence,andrecovery.JCellPhysiol,2013,228(2),292-297.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792/p>